Actively Recruiting
Evaluating Anisodine Hydrobromide with Endovascular Thrombectomy for Acute Ischemic Stroke Randomized Controlled Study on Treatment Safety and Efficacy
Led by Capital Medical University · Updated on 2026-10-13
204
Participants Needed
13
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke who are undergoing endovascular thrombectomy. This phase 2, multicenter, randomized, double-blind, placebo-controlled study aims to understand how this drug affects patients treated within 24 hours of stroke onset. The trial involves adult participants aged 18 to 80 years with specific types of large-vessel occlusion in the brain. Participants will be randomly assigned to receive either anisodine hydrobromide or a placebo, both given alongside standard endovascular thrombectomy care. The drug is administered as an intravenous infusion of 2 mg diluted in saline twice daily for a total of 14 doses. The placebo group receives an equivalent volume of saline infusion on the same schedule. Both groups will be monitored during follow-up to assess treatment effects and safety. During the study, participants will undergo regular evaluations including neurological assessments using NIH Stroke Scale and modified Rankin Scale scores, along with brain imaging to measure cerebral infarct volume on day 8. Additional outcome measures at 90 days include functional independence and quality of life assessments. Safety is closely monitored, and participants are followed until study completion in March 2027.
CONDITIONS
Brief Title
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
Research Team
X
Xunming Ji, PhD/MD
C
Chuanjie Wu, PhD/MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here